Aims and scope
Cancers of the Head & Neck is an open access, peer-reviewed journal dedicated to publishing articles on pre-clinical and translational research, as well as research related to the clinical management of head & neck cancers. This includes cancers of the oral cavity, pharynx, larynx, paranasal sinuses, nasal cavity and salivary glands. Articles related to the aetiology, pathophysiology, prevention, diagnosis, treatment and survivorship of these cancers are all considered.
Topical areas of interest include, but are not limited to:
• Biologic insights and novel targets
• HPV associated cancers of the head and neck, including epidemiological studies
• Biomarker studies – including applications and limitations of currently established biomarkers, reports on new and emerging biomarkers and the shift from prognostic to predictive use biomarkers to personalise treatment
• In vitro and in silico modelling
• Clinical trials of novel agents or paradigm
• Advances in immunotherapy and integrating immunotherapeutic approaches into care
• Novel aspects of surgical management including use of minimally invasive surgical techniques in conjunction with chemoradiotherapy
• Patient related outcomes, including survivorship issues, follow-up care, rehabilitation and speech therapy
As an open access, online journal, Cancers of the Head & Neck provides a high visibility platform for the publication of original research and expert reviews. The journal serves as essential reading for medical oncologists, radiation oncologists, surgical oncologists, speech therapists, rehabilitation medicine providers, as well as basic and translational researchers, drug developers, dental practitioner and other allied healthcare professionals
All articles published by Cancers of the Head & Neck are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Cancers of the Head & Neck you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Cancers of the Head & Neck therefore levies an article-processing charge of £1370.00/$2145.00/€1745.00 for each article accepted for publication.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
BioMed Central provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
We are working closely with relevant indexing services including PubMed Central and Web of Science (Clarivate Analytics) to ensure that articles published in Cancers of the Head & Neck will be available in their databases, when appropriate.
Cancers of the Head & Neck operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.
The benefit of single-blind peer review is that it is the traditional method of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
After initial screening for general suitability by the Editor-in-Chief, a manuscript is assigned to the appropriate Section Editor who reviews and ensures manuscripts are assessed by two or more experts in the field. Reviewers are asked to evaluate whether the manuscript is scientifically sound and coherent and whether the manuscript should be accepted, rejected or revised. Final decisions are made by the Editor-in-Chief based on the recommendations of Section Editors and reviewer reports. Where necessary, the Editorial Board will be consulted.
All manuscripts submitted to Cancers of the Head & Neck should adhere to BioMed Central's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Citing articles in Cancers of the Head & Neck
Articles in Cancers of the Head & Neck should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Cancers Head Neck [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Cancers Head Neck 2009, 1:115. refers to article 115 from Volume 1 of the journal.
Appeals and complaints
If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher.
Why publish your article in Cancers of the Head & Neck
Cancers of the Head & Neck's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Cancers of the Head & Neck offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in Cancers of the Head & Neck gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Cancers of the Head & Neck are included in article alerts and regular email updates. Some may be highlighted on Cancers of the Head & Neck’s pages and on the BioMed Central homepage.
In addition, articles published in Cancers of the Head & Neck may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Cancers of the Head & Neck. A list of articles recently press-released by journals published by BioMed Central is available here.
As an author of an article published in Cancers of the Head & Neck you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.